文献速递心脑血管急症

预防性经皮冠状动脉介入治疗与单纯最佳药物治疗对易损动脉粥样硬化冠脉斑块的疗效(PREVENT):多中心、开放标签、随机对照试验

Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial.
PubMed 文献 · Lancet · 2024-04-08
一句话结论对血流动力学不限流(FFR>0.80)的易损冠脉斑块,预防性PCI联合最佳药物治疗较单纯最佳药物治疗显著降低2年主要不良心脏事件(0.4% vs 3.4%,绝对差-3.0个百分点,p=0.0003),作者认为支持将非限流高危易损斑块纳入PCI适应证。

PREVENT为多中心、开放标签、随机对照试验,在4个国家15家研究中心纳入1606例经冠脉内影像识别、血流不限流(FFR>0.80)的易损冠脉斑块患者,1:1随机至预防性PCI+最佳药物治疗或单纯最佳药物治疗。2年主要终点(心源性死亡、靶血管心肌梗死、缺血驱动靶血管血运重建或因不稳定或进展性心绞痛住院的复合终点)在PCI组发生3例(0.4%)、药物组27例(3.4%),绝对差-3.0个百分点(95%CI -4.4至-1.8),p=0.0003。严重临床或不良事件两组无差异:死亡4例(0.5%)vs 10例(1.3%),心肌梗死9例(1.1%)vs 13例(1.7%)。作者认为这是首个显示易损斑块局灶治疗潜在效果的大型试验,支持考虑将非限流高危易损斑块扩展为PCI适应证。

要点

  • 入组标准:年龄≥18岁、冠脉内影像识别为易损斑块、血流不限流(FFR>0.80);预防性PCI+最佳药物治疗vs单纯最佳药物治疗。
  • 2年主要复合终点:PCI组3例(0.4%)vs药物组27例(3.4%),绝对差-3.0个百分点(95%CI -4.4至-1.8),p=0.0003。
  • 主要终点各组分方向一致;严重临床或不良事件两组无差异:死亡4例(0.5%)vs 10例(1.3%),绝对差-0.8个百分点(95%CI -1.7至0.2);心肌梗死9例(1.1%)vs 13例(1.7%),绝对差-0.5个百分点(95%CI -1.7至0.6)。
  • 作者认为:PREVENT是首个显示易损斑块局灶治疗潜在效果的大型试验,支持考虑将非限流高危易损斑块扩展为PCI适应证。
  • 2年主要终点评估完成1556例(97%):PCI组780例,药物组776例。

适用人群与场景

  • 年龄18岁或以上、经冠脉内影像识别为血流不限流(FFR>0.80)的易损冠脉斑块患者。
  • 研究在4个国家(韩国、日本、台湾和新西兰)的15家研究医院开展。

诊断标准与关键阈值

  • 入组条件:经冠脉内影像识别的易损冠脉斑块,且血流不限流(FFR>0.80)。

处置流程与药物剂量

  • 随机1:1分配至预防性PCI+最佳药物治疗或单纯最佳药物治疗,区组大小4或6,按糖尿病状态和非研究靶血管PCI实施情况分层。
  • 所有入组患者每年随访,直至最后入组患者随机后满2年。

研究设计与关键结果

  • 研究类型:多中心、开放标签、随机对照试验;15家研究医院,4个国家;2015年9月23日至2021年9月29日筛查5627例,入组1606例,随机至PCI组803例、单纯最佳药物治疗组803例;男性1177例(73%),女性429例(27%)。
  • 2年主要终点评估完成1556例(97%):PCI组780例,药物组776例。
  • 主要终点(心源性死亡、靶血管心肌梗死、缺血驱动靶血管血运重建或因不稳定或进展性心绞痛住院的复合终点,意向性治疗人群2年):PCI组3例(0.4%)vs药物组27例(3.4%),绝对差-3.0个百分点(95%CI -4.4至-1.8),p=0.0003。
  • 主要复合终点各组分效应方向一致。
  • 严重临床或不良事件:死亡PCI组4例(0.5%)vs药物组10例(1.3%),绝对差-0.8个百分点(95%CI -1.7至0.2);心肌梗死PCI组9例(1.1%)vs药物组13例(1.7%),绝对差-0.5个百分点(95%CI -1.7至0.6)。

证据类型、等级与局限

  • 证据类型:多中心、开放标签、随机对照试验(PREVENT),注册号ClinicalTrials.gov NCT02316886。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为:PREVENT是首个显示易损斑块局灶治疗潜在效果的大型试验,这些发现支持考虑将非限流高危易损斑块扩展为PCI适应证。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Acute coronary syndrome and sudden cardiac death are often caused by rupture and thrombosis of lipid-rich atherosclerotic coronary plaques (known as vulnerable plaques), many of which are non-flow-limiting. The safety and effectiveness of focal preventive therapy with percutaneous coronary intervention of vulnerable plaques in reducing adverse cardiac events are unknown. We aimed to assess whether preventive percutaneous coronary intervention of non-flow-limiting vulnerable plaques improves clinical outcomes compared with optimal medical therapy alone.

METHODS: PREVENT was a multicentre, open-label, randomised controlled trial done at 15 research hospitals in four countries (South Korea, Japan, Taiwan, and New Zealand). Patients aged 18 years or older with non-flow-limiting (fractional flow reserve >0·80) vulnerable coronary plaques identified by intracoronary imaging were randomly assigned (1:1) to either percutaneous coronary intervention plus optimal medical therapy or optimal medical therapy alone, in block sizes of 4 or 6, stratified by diabetes status and the performance of percutaneous coronary intervention in a non-study target vessel. Follow-up continued annually in all enrolled patients until the last enrolled patient reached 2 years after randomisation. The primary outcome was a composite of death from cardiac causes, target-vessel myocardial infarction, ischaemia-driven target-vessel revascularisation, or hospitalisation for unstable or progressive angina, assessed in the intention-to-treat population at 2 years. Time-to-first-event estimates were calculated with the Kaplan-Meier method and were compared with the log-rank test. This report is the principal analysis from the trial and includes all long-term analysed data. The trial is registered at ClinicalTrials.gov, NCT02316886, and is complete.

FINDINGS: Between Sept 23, 2015, and Sept 29, 2021, 5627 patients were screened for eligibility, 1606 of whom were enrolled and randomly assigned to percutaneous coronary intervention (n=803) or optimal medical therapy alone (n=803). 1177 (73%) patients were men and 429 (27%) were women. 2-year follow-up for the primary outcome assessment was completed in 1556 (97%) patients (percutaneous coronary intervention group n=780; optimal medical therapy group n=776). At 2 years, the primary outcome occurred in three (0·4%) patients in the percutaneous coronary intervention group and in 27 (3·4%) patients in the medical therapy group (absolute difference -3·0 percentage points [95% CI -4·4 to -1·8]; p=0·0003). The effect of preventive percutaneous coronary intervention was directionally consistent for each component of the primary composite outcome. Serious clinical or adverse events did not differ between the percutaneous coronary intervention group and the medical therapy group: at 2 years, four (0·5%) versus ten (1·3%) patients died (absolute difference -0·8 percentage points [95% CI -1·7 to 0·2]) and nine (1·1%) versus 13 (1·7%) patients had myocardial infarction (absolute difference -0·5 percentage points [-1·7 to 0·6]).

INTERPRETATION: In patients with non-flow-limiting vulnerable coronary plaques, preventive percutaneous coronary intervention reduced major adverse cardiac events arising from high-risk vulnerable plaques, compared with optimal medical therapy alone. Given that PREVENT is the first large trial to show the potential effect of the focal treatment for vulnerable plaques, these findings support consideration to expand indications for percutaneous coronary intervention to include non-flow-limiting, high-risk vulnerable plaques.

FUNDING: The CardioVascular Research Foundation, Abbott, Yuhan Corp, CAH-Cordis, Philips, and Infraredx, a Nipro company.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Park SJ, Ahn JM, Kang DY, et al. Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial. Lancet. 2024. PMID: 38604213. doi:10.1016/S0140-6736(24)00413-6

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。